Testosterone, like many anabolic steroids, was classified as a controlled substance in 1991. Testosterone is administered parenterally in normal and delayed-release (depot) forms. In September 1995, the FDA approved testosterone transdermal patches (Androderm), and many transdermal forms and brands are now available including implants, gels, and topical solutions. A testosterone buccal system, Striant, was FDA-approved in July 2003; Striant is a mucoadhesive product that adheres to the buccal mucosa and provides a controlled and sustained release of testosterone. In May 2014, the FDA approved an intranasal gel formulation of testosterone (Natesto). A transdermal patch (Intrinsa) for hormone replacement in women is under investigation; the daily dosages used in women are much lower than for products used in males. The FDA refused approval for Intrinsa in 2004 stating that more data regarding safety, especially in relation to cardiovascular and breast health, were required.
Primary hypogonadism (congenital or acquired): Testicular failure due to diseases and conditions in the body such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter Syndrome, chemotherapy, or toxic damage from alcohol or heavy metals; these men usually have low serum testosterone levels and gonadotropins (FSH, LH) above normal range Hypogonadotropic hypogonadism (congenital or acquired): Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation; these men have low testosterone serum concentrations but have gonadotropins in the normal or low range.
While we are familiar with the Propionate ester the remaining three esters that create Sustanon-250 are almost always found as part of a mixture or compounded anabolic androgenic steroid .
Developed by Organon, the original idea behind Sustanon-250 was to provide a testosterone form well-suited for hormone replacement therapy that would only needed to be administered once every few weeks and for all intense purposes the idea was a success. For the performance enhancing athlete Sustanon-250 can be a fine choice but the idea of injecting only once or twice a month is not applicable here. As a performance enhancer this testosterone like all forms will need to be administered on a more frequent basis. This mixture carries with it two fast, short esters, Propionate and Pheylpropionate, a longer more moderate ester Isocaproate and the very slow and long Decanoate ester. In order to keep testosterone levels stable and at their peak most athletes will inject Sustanon-250 at a minimum of every 3 days and more commonly every other day for optimal results.
For more info see: Sustanon-250